Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance
Tóm tắt
Từ khóa
Tài liệu tham khảo
Singh Y, Palombo M, Sinko PJ: Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem. 2008, 15 (18): 1802-1826. 10.2174/092986708785132997
Piccart M: Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer. Clin Breast Cancer. 2008, 8 (Suppl 3): S100-113. 10.3816/CBC.2008.s.006
Marmor MD, Skaria KB, Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys. 2004, 58 (3): 903-913.
Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003, 284 (1): 99-110. 10.1016/S0014-4827(02)00099-X
Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA. 1999, 96 (9): 4995-5000. 10.1073/pnas.96.9.4995
Citri A, Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006, 7 (7): 505-516. 10.1038/nrm1962
Zaczek A, Brandt B, Bielawski KP: The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol. 2005, 20 (3): 1005-1015.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002, 20 (3): 719-726. 10.1200/JCO.20.3.719
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344 (11): 783-792. 10.1056/NEJM200103153441101
Nahta R, Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett. 2006, 232 (2): 123-138. 10.1016/j.canlet.2005.01.041
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999, 17 (9): 2639-2648.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisanski TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005, 353 (16): 1673-1684. 10.1056/NEJMoa052122
Massague J: G1 cell-cycle control and cancer. Nature. 2004, 432 (7015): 298-306. 10.1038/nature03094
Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE: ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol. 2000, 20 (9): 3210-3223. 10.1128/MCB.20.9.3210-3223.2000
Seville LL, Shah N, Westwell AD, Chan WC: Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr Cancer Drug Targets. 2005, 5 (3): 159-170. 10.2174/1568009053765816
Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 1999, 98 (6): 859-869. 10.1016/S0092-8674(00)81519-6
Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, Meyyappan M, Rosfjord EC, Rabindran SK: Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat. 2006, 95 (2): 185-194. 10.1007/s10549-005-9066-y
Haberichter T, Madge B, Christopher RA, Yoshioka N, Dhiman A, Miller R, Gendelman R, Aksenov SV, Khalil IG, Dowdy SF: A systems biology dynamical model of mammalian G1 cell cycle progression. Mol Syst Biol. 2007, 3: 84- 10.1038/msb4100126
Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev. 1998, 12 (15): 2245-2262. 10.1101/gad.12.15.2245
Ptitsyn AA, Weil MM, Thamm DH: Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinformatics. 2008, 9 (Suppl 9): S8- 10.1186/1471-2105-9-S9-S8
Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M: Drug-target network. Nat Biotechnol. 2007, 25 (10): 1119-1126. 10.1038/nbt1338
Faure A, Naldi A, Chaouiya C, Thieffry D: Dynamical analysis of a generic Boolean model for the control of the mammalian cell cycle. Bioinformatics. 2006, 22 (14): e124-131. 10.1093/bioinformatics/btl210
Gonzalez AG, Naldi A, Sanchez L, Thieffry D, Chaouiya C: GINsim: a software suite for the qualitative modelling, simulation and analysis of regulatory networks. Biosystems. 2006, 84 (2): 91-100. 10.1016/j.biosystems.2005.10.003
Sahin O, Lobke C, Korf U, Appelhans H, Sultmann H, Poustka A, Wiemann S, Arlt D: Combinatorial RNAi for quantitative protein network analysis. Proc Natl Acad Sci USA. 2007, 104 (16): 6579-6584. 10.1073/pnas.0606827104
Loebke C, Sueltmann H, Schmidt C, Henjes F, Wiemann S, Poustka A, Korf U: Infrared-based protein detection arrays for quantitative proteomics. Proteomics. 2007, 7 (4): 558-564. 10.1002/pmic.200600757
Takahashi-Yanaga F, Taba Y, Miwa Y, Kubohara Y, Watanabe Y, Hirata M, Morimoto S, Sasaguri T: Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3beta and degrades cyclin D1 in mammalian cells. J Biol Chem. 2003, 278 (11): 9663-9670. 10.1074/jbc.M205768200
Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A: The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta. 2006, 1766 (1): 120-139.
Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL: Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA. 1994, 91 (17): 8132-8136. 10.1073/pnas.91.17.8132
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995, 269 (5224): 682-685. 10.1126/science.7624798
Kumar N, Wolf-Yadlin A, White FM, Lauffenburger DA: Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data. PLoS Comput Biol. 2007, 3 (1): e4- 10.1371/journal.pcbi.0030004
Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, Kholodenko BN: Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. Mol Syst Biol. 2007, 3: 144- 10.1038/msb4100188
Novak B, Tyson JJ: A model for restriction point control of the mammalian cell cycle. J Theor Biol. 2004, 230 (4): 563-579. 10.1016/j.jtbi.2004.04.039
Tetsu O, McCormick F: Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003, 3 (3): 233-245. 10.1016/S1535-6108(03)00053-9
Park K, Kwak K, Kim J, Lim S, Han S: c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol. 2005, 36 (6): 634-639. 10.1016/j.humpath.2005.04.016
Le XF, Pruefer F, Bast RC: HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle. 2005, 4 (1): 87-95.
Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI: Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer. 2005, 12 (Suppl 1): S99-S111. 10.1677/erc.1.01005
Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 2003, 144 (3): 1032-1044. 10.1210/en.2002-220620
Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ: P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004, 64 (11): 3981-3986. 10.1158/0008-5472.CAN-03-3900
Amit I, Wides R, Yarden Y: Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol. 2007, 3: 151- 10.1038/msb4100195
Benjamini Y, Hochberg Y: Controlling the false discovery rate – A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B-Methodological. 1995, 57 (1): 289-300.